XCancer
Curium

Phase 3 Trial of Copper Cu 64 PSMA I&T PET/CT Imaging in Men with Suspected Biochemical Recurrence of Prostate Cancer (Solar-Recur)

Description:

Solar-Recur is a single-arm prospective study. Local read of the copper Cu 64 PSMA I&T PET/CT can be used to inform patient management. For the primary endpoints, PET/CT scans will be read by blinded independent reviewers.

Sponsor:

Curium

Contacts:

Darcy Denner, Ph.D. (Clinical Trial Director)

darcy.denner@curiumpharma.com

Government Study Link:

NCT062356099 - Click here to see study on

ClinicalTrials.gov

Isotope(s):
Target(s):
Inclusion
  • BCR of PC: Patients w/prior RP: PSA >.2 ng/mL w/confirm PSA value >.2, or w/prior radiation: 2ng/mL PSA rise over nadir
  • Male aged ≥18 years
  • Prior RP (>6 weeks prior to screening) or radiation therapy (>1 year prior to screening) with curative intent
  • Histologically proven prostate adenocarcinoma
Exclusion
  • ADT or other therapies targeting the Androgen pathway within 3 months. Pts w/rise in PSA while on ADT for >6 months
  • PSMA PET within 90 days prior to enrollment

Patient Education

Publications

Publications Not Yet Provided

Locations

Loading...